<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716051</url>
  </required_header>
  <id_info>
    <org_study_id>I15037/WILSON</org_study_id>
    <nct_id>NCT02716051</nct_id>
  </id_info>
  <brief_title>Wholebody MRI In Lung Cancer StagiNg</brief_title>
  <acronym>WISLON</acronym>
  <official_title>Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in&#xD;
      detection of nodes in patients with cell lung cancer (NSCLC).&#xD;
&#xD;
      However, the cardiorespiratory synchronization in the MRI, allowing acquisition of&#xD;
      synchronous images with breathing and heart movements should increase the sensitivity of&#xD;
      detection of pathologic mediastinal lymph nodes.&#xD;
&#xD;
      Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as&#xD;
      informative as PET, while being less expensive, not radiant.&#xD;
&#xD;
      The purpose of this study is to evaluate the performance of whole-body MRI with diffusion&#xD;
      with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are&#xD;
      known to be less well detected by MRI) compared to PET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Th consistency of the locations of mediastinal lesions</measure>
    <time_frame>Day 1</time_frame>
    <description>Node localization according to MRI and PET scan measurements on the same day</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At day 1 , in the morning, patient will undergo an PET analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Whole body MRI with cardiac and pulmonary synchronization</description>
    <arm_group_label>MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years,&#xD;
&#xD;
          -  Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed,&#xD;
&#xD;
          -  Patient potentially eligible for curative treatment, but no no treatment started,&#xD;
&#xD;
          -  Patients for whom a PET scan and MRI are planned&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          -  claustrophobia,&#xD;
&#xD;
          -  Implantable Medical Device&#xD;
&#xD;
          -  not compatible pacemaker type or heart valve, metal splinters eye)&#xD;
&#xD;
          -  Pregnant or lactating women,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

